Stellate Cell Targeting: Peptides vs. Liver Fibrosis

Liver Fibrosis Peptides

3 targeting strategies

Three peptide-based approaches now target activated hepatic stellate cells directly: integrin-binding RGD peptides, PDGF receptor-targeting cyclic peptides, and vitamin A receptor-guided nanoparticles.

Mostafa et al., Molecular Pharmaceutics, 2025

Mostafa et al., Molecular Pharmaceutics, 2025

View as image

Liver fibrosis has no FDA-approved drug treatment. Every antifibrotic therapy that has reached clinical trials for liver disease has either failed or is still in development. The core problem is not a lack of molecules that can slow or reverse fibrosis in a test tube. The problem is getting those molecules to the right cells without damaging everything else. For a broader overview of antifibrotic strategies, see the pillar article on collagen peptide markers in liver fibrosis.

The right cells are hepatic stellate cells (HSCs). In healthy liver, HSCs are quiescent, storing vitamin A in lipid droplets and doing little else. When the liver is injured, whether by alcohol, hepatitis virus, fatty liver disease, or toxins, HSCs activate. They transform into myofibroblast-like cells that produce massive amounts of extracellular matrix proteins, primarily collagen types I and III. Activated HSCs are responsible for approximately 80% of the collagen deposited during liver fibrosis. Kill or deactivate these cells, and fibrosis stops. The challenge is reaching them selectively.

Why Stellate Cells Are the Target

The liver contains multiple cell types: hepatocytes (the workhorses of metabolism, making up 60-70% of liver cells), Kupffer cells (resident macrophages), sinusoidal endothelial cells, cholangiocytes (bile duct cells), and hepatic stellate cells (5-8% of all liver cells).

In fibrosis, the damage cascade works like this: liver injury triggers inflammation. Inflammatory signals (TGF-beta1, PDGF, angiotensin II, reactive oxygen species) activate quiescent HSCs. Activated HSCs proliferate, migrate to sites of injury, and begin depositing extracellular matrix at rates far exceeding normal turnover. Over months to years, this excess collagen accumulates as scar tissue, distorting liver architecture and eventually leading to cirrhosis.

The activation process involves dramatic changes in HSC biology:

• Loss of vitamin A lipid droplets (the quiescent storage function disappears)
• Upregulation of alpha-smooth muscle actin (aSMA), giving cells contractile ability
• Massive increase in collagen I and III production
• Upregulation of surface receptors including integrin αvβ3, PDGFR-beta, and mannose-6-phosphate/IGF-II receptors
• Increased production of tissue inhibitors of metalloproteinases (TIMPs), which block the enzymes that would normally degrade excess collagen

Each of these activation markers represents a potential targeting handle. Peptides that bind specifically to receptors upregulated on activated HSCs can serve as address labels, directing drug-loaded nanoparticles to the right cells while sparing hepatocytes and other liver cell populations.

Strategy 1: RGD Peptides Targeting Integrin αvβ3

Integrin αvβ3 is minimally expressed on quiescent HSCs and healthy hepatocytes. During activation, HSCs dramatically upregulate this receptor. This differential expression makes αvβ3 an attractive target for selective delivery.

The RGD (Arg-Gly-Asp) tripeptide motif is the canonical integrin-binding sequence. Cyclic RGD peptides (cRGD) have higher affinity and selectivity for αvβ3 than linear RGD, because the cyclic constraint pre-organizes the binding motif into the conformation recognized by the receptor.

Early work demonstrated that cRGD-labeled liposomes accumulated preferentially in fibrotic liver regions when administered to rats with CCl4-induced fibrosis. The liposomes bypassed healthy hepatocytes and concentrated in areas of active stellate cell proliferation.

Liu and colleagues (2025) advanced this approach with ROS-responsive micelles bearing a dual-function peptide, cRGDfK-R6.^[1] The cRGDfK segment targets αvβ3 integrin on activated HSCs. The R6 segment is a cell-penetrating peptide that enhances intracellular delivery once the micelle reaches the target cell. The micelles are designed to disassemble in response to the high reactive oxygen species (ROS) levels found inside activated HSCs, releasing their therapeutic cargo only after reaching the target.

In fibrotic mouse models, these micelles showed enhanced drug accumulation in activated HSCs compared to non-targeted formulations, and produced measurable antifibrotic effects including reduced collagen deposition and decreased aSMA expression.

Strategy 2: PDGFR-Beta Targeting Peptides

Platelet-derived growth factor receptor-beta (PDGFR-beta) is the most potent mitogen for activated HSCs. Its expression increases 5-10 fold during HSC activation, making it both a driver of fibrosis and a targeting opportunity.

The cyclic peptide C*SRNLIDC* was designed based on the receptor-binding residues of the PDGF B-chain, the natural ligand for PDGFR-beta. This peptide binds specifically to PDGFR-beta on activated HSCs. When conjugated to interferon-gamma (IFN-gamma, an antifibrotic cytokine), the peptide-IFN-gamma conjugate showed specific binding to cultured HSCs, inhibited their activation, and significantly reduced fibrogenesis in both acute liver injury and CCl4-induced chronic liver fibrosis animal models.

Mostafa and colleagues (2025) used a PDGFR-beta peptide-modified chitosan nanoparticle to deliver anti-TGF-beta1 siRNA directly to HSCs.^[2] TGF-beta1 is the master driver of HSC activation and collagen production. Silencing TGF-beta1 expression specifically in HSCs, rather than systemically, avoids the immunosuppressive effects that would result from body-wide TGF-beta1 suppression. The PDGFR-beta peptide guided the nanoparticles to activated HSCs, where the siRNA knocked down TGF-beta1 expression and reduced fibrosis markers in animal models.

This approach illustrates the power of peptide targeting for gene therapy. siRNA is potent but fragile: it degrades rapidly in blood, cannot cross cell membranes without a carrier, and affects every cell it enters nonselectively. Peptide-guided nanoparticles solve all three problems: protecting the siRNA, delivering it to the right cells, and enabling intracellular release.

Strategy 3: Vitamin A Receptor Targeting

Quiescent HSCs store 80% of the body's vitamin A (retinol) in cytoplasmic lipid droplets. Even after activation, HSCs retain some capacity for retinol uptake through retinol-binding protein receptors. This natural uptake pathway can be exploited for targeted delivery.

Vitamin A-functionalized lipid nanoparticles carrying siRNA against HSP47 (heat shock protein 47, a collagen-specific chaperone required for collagen secretion) reached clinical trials (NCT02227459). HSP47 knockdown prevents activated HSCs from secreting the collagen they produce, effectively blocking fibrosis at the final step.

This was the first clinical test of a stellate cell-targeted antifibrotic therapy. The vitamin A targeting approach differs from the peptide approaches in that it uses a small molecule (retinol) rather than a peptide as the targeting ligand, but the principle is identical: exploit a receptor that is preferentially expressed on the target cell to achieve selective delivery.

Thymosin Beta-4: A Peptide That Acts on HSCs Directly

Some peptides do not target HSCs for drug delivery but instead act directly on stellate cell biology.

Choi and colleagues (2023) demonstrated that thymosin beta-4 (TB4) inhibits LPS and ATP-induced activation of hepatic stellate cells by regulating the NLRP3 inflammasome pathway.^[3] The NLRP3 inflammasome is an intracellular danger sensor that drives inflammation and fibrosis. TB4 suppressed its activation in HSCs, reducing the production of pro-inflammatory and pro-fibrotic mediators.

Kim and colleagues (2023) provided complementary evidence using genetic deletion: targeted removal of the thymosin beta-4 gene specifically in HSCs ameliorated liver fibrosis in mouse models.^[4] Paradoxically, this means endogenous TB4 in HSCs may contribute to fibrosis under certain conditions, while exogenous TB4 treatment may have anti-inflammatory effects through different mechanisms. The relationship between TB4 and HSC biology is more complex than simple pro- or anti-fibrotic categorization.

Substance P: A Peptide That Makes Fibrosis Worse

Not all peptide-HSC interactions are therapeutic. Substance P, the neuropeptide involved in pain and inflammation signaling, directly promotes hepatic stellate cell proliferation and activation.

Peng and colleagues (2017) showed that substance P activates HSCs through the TGF-beta1/Smad3 signaling pathway, the same master fibrotic pathway that PDGFR-beta targeting aims to suppress.^[5] This finding connects the nervous system to liver fibrosis progression and may partly explain why stress and chronic pain conditions are associated with worse liver disease outcomes. Understanding which peptides drive HSC activation helps define which pathways to block.

GLP-1 Agonists and Stellate Cells: An Indirect Effect

GLP-1 receptor agonists (semaglutide, tirzepatide) are showing striking effects on liver fibrosis in clinical trials for MASH (metabolic dysfunction-associated steatohepatitis). But the mechanism may not involve direct HSC effects.

Da Silva Lima and colleagues (2024) tested GLP-1 and GIP agonism directly on human hepatocytes and hepatic stellate cells in culture and found no direct antifibrotic actions.^[6] The clinical fibrosis improvement seen with GLP-1 drugs appears to be indirect: by reducing liver fat, improving insulin sensitivity, and reducing inflammation, GLP-1 agonists remove the stimuli that activate HSCs in the first place.

However, Fan and colleagues (2025) showed that liraglutide does inhibit rat HSC proliferation under high-glucose conditions, suggesting that the GLP-1 effect on stellate cells may be context-dependent.^[7] Mantovani and colleagues (2025) published a meta-analysis confirming that GLP-1 receptor agonists improve MASH and liver fibrosis overall, regardless of the specific cellular mechanism.^[8]

For more on how MASH is being targeted by peptide therapies and broader peptide approaches to liver fibrosis, the dedicated articles cover the full landscape.

What Remains Between Lab and Clinic

The delivery gap. Most HSC-targeting studies use animal models of CCl4-induced fibrosis, which produces a relatively uniform injury pattern. Human liver fibrosis is heterogeneous: different diseases produce different patterns of stellate cell activation, and the same liver may contain zones of active fibrosis, established scar, and relatively normal tissue. Whether peptide-guided nanoparticles can navigate this heterogeneity in humans is unknown.

Manufacturing complexity. Peptide-functionalized nanoparticles are complex drug products. Each component (the therapeutic cargo, the nanoparticle carrier, the peptide targeting ligand, and the linker chemistry connecting them) must be manufactured reproducibly and at scale. This complexity has historically slowed the clinical translation of targeted nanomedicines.

Safety of stellate cell killing. HSCs have functions beyond collagen production. They regulate liver blood flow, participate in immune surveillance, and contribute to liver regeneration after acute injury. Complete elimination of HSCs could have unintended consequences. The most promising approaches aim to deactivate HSCs (reverting them to quiescence) rather than killing them.

Receptor downregulation. Heavily activated HSCs may downregulate the very receptors being targeted. If integrin αvβ3 or PDGFR-beta expression declines in late-stage cirrhosis, peptide-guided delivery could become less effective precisely when it is most needed. Combining multiple targeting peptides on the same nanoparticle (dual-targeting) is one proposed solution, but adds manufacturing complexity.

Fibrosis reversal vs. prevention. Most targeting studies measure reduced fibrosis progression. Whether HSC-targeted therapies can reverse established cirrhosis, dissolving scar tissue that has already formed, is a harder question. Reversal requires not just stopping new collagen deposition but activating matrix metalloproteinases to degrade existing scar, and overcoming the TIMP overproduction that activated HSCs maintain.

The Bottom Line

Peptide-based targeting of hepatic stellate cells represents the most precise approach to liver fibrosis treatment currently in development. Three targeting strategies (RGD/integrin, PDGFR-beta peptides, and vitamin A receptor) can selectively deliver antifibrotic drugs and gene therapies to the cells that produce liver scar tissue. One approach has reached clinical trials. The field is moving from proof-of-concept in animal models toward the manufacturing and regulatory challenges that precede human testing, with GLP-1 agonists providing an indirect but clinically validated parallel path.

Frequently Asked Questions

What are hepatic stellate cells and why do they matter?

Hepatic stellate cells (HSCs) are specialized liver cells that make up 5-8% of all liver cells. In healthy liver, they store vitamin A and remain quiescent. When the liver is injured, HSCs activate and transform into collagen-producing myofibroblasts responsible for approximately 80% of the scar tissue in liver fibrosis. Targeting these cells specifically is the most direct approach to stopping or reversing liver scarring.

How do peptides target stellate cells specifically?

Activated HSCs upregulate specific surface receptors that quiescent HSCs and healthy hepatocytes do not express at high levels. Peptides that bind these receptors serve as targeting ligands on drug-carrying nanoparticles. The three main targets are integrin αvβ3 (bound by cyclic RGD peptides), PDGFR-beta (bound by the cyclic peptide CSRNLIDC), and retinol-binding protein receptors (exploited by vitamin A-functionalized carriers).

Is there an FDA-approved drug for liver fibrosis?

No. As of 2026, there is no FDA-approved antifibrotic drug for any form of liver fibrosis or cirrhosis. GLP-1 receptor agonists (resmetirom received approval for MASH in 2024, but for steatohepatitis specifically) represent the closest class, showing fibrosis improvement as a secondary outcome. HSC-targeted peptide therapies remain in preclinical and early clinical development.

Can liver fibrosis be reversed?

Evidence from both animal studies and human clinical observations shows that liver fibrosis can partially reverse if the underlying cause is removed (e.g., treating hepatitis, stopping alcohol use). Whether targeted HSC therapies can accelerate this reversal or achieve it when the underlying cause persists is an active area of research. The challenge is not just stopping new scar formation but degrading existing collagen deposits.

Do GLP-1 drugs like semaglutide help liver fibrosis?

Meta-analysis data shows GLP-1 receptor agonists improve MASH and liver fibrosis. However, direct testing on human HSCs showed no direct antifibrotic effect of GLP-1 agonism. The benefit appears indirect: by reducing liver fat, improving insulin sensitivity, and reducing inflammation, GLP-1 drugs remove the stimuli that keep HSCs activated. This is clinically effective but mechanistically distinct from the targeted approaches described in this article.

Has any stellate cell-targeted therapy been tested in humans?

Yes, one approach has reached clinical trials. A vitamin A-functionalized lipid nanoparticle carrying siRNA against HSP47 (a collagen chaperone) was tested in the clinical trial NCT02227459. This was the first human test of a therapy designed to target stellate cells specifically. Peptide-based targeting approaches (using RGD or PDGFR-beta peptides) remain in preclinical development as of 2026.